|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
Apr 2007 |
£1,245 |
100% |
Non-Small Cell Lung Cancer - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
98% |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
Apr 2008 |
£7,210 |
98% |
|
Targeted Therapeutics in Non-Small Cell Lung Cancer
|
Apr 2007 |
£1,295 |
98% |
|
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
|
Nov 2009 |
£945 |
91% |
|
Lung Cancer Drug Pipeline Update 2011
|
Feb 2011 |
£1,245 |
91% |
|
Lung Cancer Drug Pipeline Update 2009
|
Jan 2009 |
£1,245 |
91% |
|
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
|
Jul 2011 |
£1,620 |
89% |
|
Cancer Therapies: Technologies and Global Markets
|
Jan 2008 |
£3,065 |
89% |
Pipeline Insight: Small Molecule Targeted Cancer Therapies
New targets set to drive growth
|
Apr 2010 |
£7,210 |
88% |
Commercializing Cancer Vaccines
A Decision Support Tool for Optimizing the Pipeline
|
Oct 2010 |
£1,620 |
88% |
Commercializing Apoptotic Drugs in Cancer
The Faster Route to Consider Your Options and Position of Others
|
Dec 2011 |
£2,035 |
87% |
Cancer Vaccines
Aim and Shoot
|
May 2008 |
£1,620 |
87% |
Pipeline Insight: Therapeutic Cancer Vaccines
Prospect of first approval set to reinvigorate interest from major companies
|
Dec 2009 |
£7,210 |
87% |
Telik, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
87% |
Commercializing Angiogenesis Affecting Drugs in Cancer
The Faster Route to Consider Your Options and Position of Others
|
Jan 2012 |
£2,035 |
87% |
Cancer Antibodies
Competitive Positioning for Success
|
Jun 2008 |
£1,620 |
86% |
Commercializing Peptides in Cancer
The Faster Route to Consider Your Options and Position of Others
|
Nov 2011 |
£2,035 |
86% |
The Global Competitive Landscape of Antibody Drug Development in Cancer
The Faster Route to Consider Your Options and Position of Others
|
Sep 2011 |
£2,035 |
84% |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
Jan 2007 |
£5,770 |
81% |
|
Cancer Cell Therapy Markets
|
Mar 2008 |
£2,150 |
80% |
Oncolytics Biotech Inc. – Product Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
80% |
|
Lung Cancer Drug Futures
|
Oct 2010 |
£1,495 |
79% |
Poniard Pharmaceuticals Inc
Premium Company Profile
|
Apr 2008 |
£315 |
79% |
RNAi
Technologies, Markets and Companies
|
Jan 2012 |
£2,590 |
79% |
Cyclacel Pharmaceuticals Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
78% |
Exelixis, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
76% |
|
Prostate Cancer Therapeutics
|
Apr 2009 |
£2,500 |
74% |
|
Cancer Vaccine Developments to 2013
|
Sep 2007 |
£1,296 |
74% |
|
Market for Bioengineered Protein Drugs; The
|
Jan 2007 |
£2,760 |
74% |
